¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

¿¬¼¼´ëÇб³ÀÇ·á¿ø ´ëÇѾÆÅäÇÇÇǺο°ÇÐȸ 18Â÷ Çмú´ëȸ : 2018-11-09

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
¿¬¼¼´ëÇб³ÀÇ·á¿ø ´ëÇѾÆÅäÇÇÇǺο°ÇÐȸ 18Â÷ Çмú´ëȸ : 2018-11-09
±³À°ÀÏÀÚ : 2018-11-09
±³À°Àå¼Ò : ¿¬¼¼´ëÇб³ÀÇ·á¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑ È¦  
±³À°ÁÖÁ¦ : ´ëÇѾÆÅäÇÇÇǺο°ÇÐȸ 18Â÷ Çмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѾÆÅäÇÇÇǺο°ÇÐȸ  
´ã´çÀÚ : ¼Õ»ó¿í
¿¬¶ôó : 031-412-5186  
À̸ÞÀÏ : kda@derma.or.kr      
±³À°Á¾·ù : ÇǺΰú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 3Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 300,000¿ø      
ºñ°í È¸¿ø »çÀü:40,000¿ø,ÇöÀå 50,000¿ø / ºñȸ¿ø »çÀü 200,000¿ø, ÇöÀå 300,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-09 À¯ÀÏÇÑ È¦ 14:10~14:40 New treatment guideline review  ÇÑÅ¿µ(À»ÁöÀÇ´ë) 
±³À°½Ã°£ 11-09 À¯ÀÏÇÑ È¦ 14:40~15:10 Update on topical agents in AD treatment  °íÇöâ(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 11-09 À¯ÀÏÇÑ È¦ 15:10~15:40 The link between skin barrier and immune dysregulation in AD and topical treatment for acute flare  Kenshi Yamasaki(Tohoku university) 
±³À°½Ã°£ 11-09 À¯ÀÏÇÑ È¦ 16:00~16:30 The role of IL-4 and IL-13 in pathogenesis  ÀÌÁöÇö(Ä«Å縯ÀÇ´ë) 
±³À°½Ã°£ 11-09 À¯ÀÏÇÑ È¦ 16:30~17:00 Clinical practice of novel targeted agent Dupilumab in adult AD treatment  Ken Igawa(Tokyo university) 
±³À°½Ã°£ 11-09 À¯ÀÏÇÑ È¦ 17:00~17:30 The potential new target and approach  Àå¿ëÇö(°æºÏÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ¿¬¼¼´ëÇб³ÀÇ·á¿ø ´ëÇѾÆÅäÇÇÇǺο°ÇÐȸ 18Â÷ Çмú´ëȸ : 2018-11-09""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Á¦95Â÷ ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ Á¾ÇÕÇмú´ëȸ(KoreAnesthesia 2018) : 2018-11-09
´ÙÀ½±Û ´ëÇѼÒÈ­±âÇÐȸ ±¤ÁÖÀü³²Áöȸ 2018 Ãß°è¼¼¹Ì³ª : 2018-11-09
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
1262 ¼­¿ï »ï¼º¼­¿ïº´¿ø 2018³â Á¦4ȸ ´ëÇÑ°¨¿°ÇÐȸ ¿©ÇàÀÇÇÐ ½ÉÆ÷Áö¾ö : 2018-10-21 0 367 2018-10-04
1261 ¼­¿ï Á¦4ȸ ´ëÇѼҾÆû¼Ò³â°úÀÇ»çȸ ÃÊÀ½ÆÄ¿öÅ©¼¥ : 2018-10-21 0 817 2018-10-04
1260 ¼­¿ï Á¦70Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãß°èÇмú´ëȸ : 2018-10-20 0 759 2018-10-04
1259 Ãæ³² Ãæ³²´ëÇб³º´¿ø Çѱ¹À¯¹æ¾ÏÇÐȸ 2018 Ãß°èÇмú´ëȸ : 2018-10-20 0 388 2018-10-04
1258 ¼­¿ï Çѱ¹ÀÇ°ú´ëÇС¤ÀÇÇÐÀü¹®´ëÇпøÇùȸ 2018 ÀÇ´ë/ÀÇÀü¿ø ±³¼ö¸¦ À§ÇÑ ¸®´õ½Ê ¿öÅ©¼ó : 2018-10-20 0 438 2018-10-04
1257 ´ëÀü ´ëÇѺñ´¢±â°úÇÐȸ 2018 Ãß°è ´ëÀüÃæûÁöȸ-Ãæûºñ´¢±â°úÇÐȸ ÇÕµ¿ ½ÉÆ÷Áö¾ö : 2018-10-20 0 724 2018-10-04
1256 ¼­¿ï ´ëÇÑ°³¿ø³»°úÀÇ»çȸ Á¦21ȸ Ãß°èÇмú´ëȸ : 2018-10-20 0 368 2018-10-04
1255 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ ¼­¿ï EGDM (Essential Guideline to Diabetes Management) : 2018-10-20 0 297 2018-10-04
1254 °æ³² ´ëÇÑ´ç´¢º´ÇÐȸ ºÎ¿ï°æÁöȸEGDM (Essential Guideline to Diabetes Management) : 2018-10-20 0 525 2018-10-04
1253 ÀÎõ °¡Ãµ´ë ±æº´¿ø ½ÉÀå³»°ú °³¿øÀÇ ¿¬¼ö°­Á 2018 : 2018-10-20 0 569 2018-10-04
1252 ¼­¿ï ´ëÇÑÀÓ»ó½Å°æ»ý¸®ÇÐȸ 2018³â Á¦22Â÷ Ãß°èÇмú´ëȸ : 2018-10-19 0 15,010 2018-10-04
1251 ¼­¿ï Á¦24Â÷ ´ëÇѼҾÆÀÓ»ó¸é¿ªÇÐȸ Ãß°èÇмú´ëȸ : 2018-10-19 0 488 2018-10-04
1250 ¼­¿ï 2018 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ãß°èÇмú´ëȸ : 2018-10-19 0 583 2018-10-04
1249 ¼­¿ï »ï¼º¼­¿ïº´¿ø The 5th Radiology Forum of Osaka University-Samsung Medical Center : 2018-10-19 0 607 2018-10-04
1248 ¼­¿ï 2018³â ´ëÇѼҾƽÅÀåÇÐȸ Ãß°èÇмú´ëȸ : 2018-10-19 0 281 2018-10-04
1331 | 1332 | 1333 | 1334 | 1335 | 1336 | 1337 | 1338 | 1339 | 1340
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷